Arch Therapeutics, Inc. (ARTH)
| Previous close | 1.1800 |
| Open | 1.1500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.1800 - 1.1800 |
| 52-week range | 0.3900 - 18.0000 |
| Volume | |
| Avg. volume | 4,116 |
| Market cap | 5.596M |
| Beta (5Y monthly) | 3.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4000 |
| Earnings date | 20 May 2024 - 24 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireArch Therapeutics Provides Year End Operational Update
Continued Strong Trends in Orders and Paid ClaimsFRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”). During its fourth fiscal quarter, the Company
- GlobeNewswire
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg UlcersFRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanc
